Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2014 6
2015 3
2016 2
2017 5
2018 4
2019 8
2020 6
2021 8
2022 12
2023 11
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

62 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial.
Paton NI, Musaazi J, Kityo C, Walimbwa S, Hoppe A, Balyegisawa A, Asienzo J, Kaimal A, Mirembe G, Lugemwa A, Ategeka G, Borok M, Mugerwa H, Siika A, Odongpiny ELA, Castelnuovo B, Kiragga A, Kambugu A; NADIA Trial Team. Paton NI, et al. Among authors: musaazi j. Lancet HIV. 2022 Jun;9(6):e381-e393. doi: 10.1016/S2352-3018(22)00092-3. Epub 2022 Apr 20. Lancet HIV. 2022. PMID: 35460601 Free article. Clinical Trial.
Dolutegravir pharmacokinetics in Ugandan patients with TB and HIV receiving standard- versus high-dose rifampicin.
Kengo A, Nabisere R, Gausi K, Musaazi J, Buzibye A, Omali D, Aarnoutse R, Lamorde M, Dooley KE, Sloan DJ, Denti P, Sekaggya-Wiltshire C. Kengo A, et al. Among authors: musaazi j. Antimicrob Agents Chemother. 2023 Nov 15;67(11):e0043023. doi: 10.1128/aac.00430-23. Epub 2023 Oct 18. Antimicrob Agents Chemother. 2023. PMID: 37850738 Free PMC article. Clinical Trial.
Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trial.
Kityo C, Mambule IK, Musaazi J, Sokhela S, Mugerwa H, Ategeka G, Cresswell F, Siika A, Kosgei J, Shah R, Naidoo L, Opiyo K, Otike C, Möller K, Kaimal A, Wambui C, Van Eygen V, Mohammed P, Addo Boateng F, Paton NI; CARES trial team. Kityo C, et al. Among authors: musaazi j. Lancet Infect Dis. 2024 Oct;24(10):1083-1092. doi: 10.1016/S1473-3099(24)00289-5. Epub 2024 May 28. Lancet Infect Dis. 2024. PMID: 38821073 Clinical Trial.
The contribution of late HIV diagnosis on the occurrence of HIV-associated tuberculosis.
Girardi E, Caro-Vega Y, Cozzi-Lepri A, Musaazi J, Carriquiry G, Castelnuovo B, Gori A, Manabe YC, Gotuzzo JE, D'arminio Monforte A, Crabtree-Ramírez B, Mussini C. Girardi E, et al. Among authors: musaazi j. AIDS. 2022 Nov 15;36(14):2005-2013. doi: 10.1097/QAD.0000000000003321. Epub 2022 Jul 15. AIDS. 2022. PMID: 35848588 Free PMC article.
Dolutegravir or Darunavir in Combination with Zidovudine or Tenofovir to Treat HIV.
Paton NI, Musaazi J, Kityo C, Walimbwa S, Hoppe A, Balyegisawa A, Kaimal A, Mirembe G, Tukamushabe P, Ategeka G, Hakim J, Mugerwa H, Siika A, Asienzo J, Castelnuovo B, Kiragga A, Kambugu A; NADIA Trial Team. Paton NI, et al. Among authors: musaazi j. N Engl J Med. 2021 Jul 22;385(4):330-341. doi: 10.1056/NEJMoa2101609. N Engl J Med. 2021. PMID: 34289276 Clinical Trial.
Impact of on-site Xpert on TB diagnosis and mortality trends in Uganda.
Walusimbi S, Najjingo I, Zawedde-Muyanja S, Musaazi J, Nyombi A, Katagira W, Ssendiwala J, Muttamba W. Walusimbi S, et al. Among authors: musaazi j. Public Health Action. 2022 Jun 21;12(2):90-95. doi: 10.5588/pha.21.0085. Public Health Action. 2022. PMID: 35734005 Free PMC article.
Pharmacokinetics of levonorgestrel and etonogestrel contraceptive implants over 48 weeks with rilpivirine- or darunavir-based antiretroviral therapy.
Nakalema S, Chappell CA, Pham M, Byakika-Kibwika P, Kaboggoza J, Walimbwa SI, Musaazi J, Nakijoba R, Mbabazi L, Kyohairwe I, Nassiwa S, Jeppson J, Winchester L, Siccardi M, Fletcher CV, Scarsi KK, Lamorde M. Nakalema S, et al. Among authors: musaazi j. J Antimicrob Chemother. 2022 Oct 28;77(11):3144-3152. doi: 10.1093/jac/dkac296. J Antimicrob Chemother. 2022. PMID: 36059130 Free PMC article.
62 results